ArticleCureus2024
The "Silent" Threat: Group G Streptococcus Peritonitis in Peritoneal Dialysis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis (PD) is a therapy for patients with end-stage renal disease (ESRD). PD carries an increased risk of peritonitis, often secondary to poor technique. A small subset of patients may present with "silent" peritonitis, or peritonitis in the absence of fever and abdominal pain, making diagnosis and treatment challenging. Identification of a causative organism can be an added barrier further delaying care. We present the case of a 95-year-old female with a history of ESRD on PD who presented with fatigue, confusion, and a lower leg wound found to have group G Streptococcus bacteremia. Treatment with intravenous antibiotics did not yield significant improvement, prompting the investigation of PD dialysate as a potential source. The patient was afebrile with persistent leukocytosis and no clinical signs of peritonitis. Yet, peritoneal fluid analysis confirmed peritonitis. This case underscores the importance of remaining cognizant of PD peritonitis in patients receiving PD therapy even in the absence of classic symptomatology. Risk factors such as advanced age, dementia, altered mentation from sepsis, or uncommon organisms may create an atypical presentation, delaying diagnosis and treatment. High rates of morbidity in peritonitis with concomitant bacteremia make early treatment even more crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.